title: Recent advances in active specific cancer vaccine treatment for colorectal cancer.
abstract: Cloning techniques to identify genes and peptides of tumor-associated antigens have created new possibilities for the immunotherapy of patients with advanced cancer. Here, we review recent clinical trials of specific cancer vaccines, mainly HLA-restricted peptides, and epitope-encoding vectors for advanced colorectal cancer (CRC). Many researchers initially focused on carcinoembryonic antigen (CEA) as an immunologic target antigen that is overexpressed on virtually all CRCs. A recombinant vaccine containing the CEA gene and dendritic cells (DCs) loaded with CEA peptide was administered to patients with CEA-elevated CRC. Although CEA-specific responses were detected, the clinical responses were limited. Recently, new types of clinical trials--namely, a personalized protocol to take into account the immunological diversity of cytotoxic T cell responses among patients and a novel cancer-testis antigen protocol that uses multiple peptides derived from genes identified by the cDNA array method--have been introduced. The personalized protocol seemed to be better than the classical (non-personalized) protocol in terms of clinical response and survival. Novel cancer-testis antigen protocols that use multiple CRC-derived peptides were recently conducted in patients with advanced CRC. The preliminary study yielded promising results regarding specific T cell responses to peptides and survival benefits. In this review, we summarize these results and discuss future perspectives.
authors.affiliation: Department of Surgery, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-sayama 589- 8511, Japan. okuno@surg.med.kindai.ac.jp
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Okuno
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Sugiura
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
authors.forename: Koji
authors.initials: K
authors.lastname: Yoshida
authors.forename: Takuya
authors.initials: T
authors.lastname: Tsunoda
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy
chemical_list: D019496:Cancer Vaccines